NEWRON PHARMACEUT. EO-20 Working Capital to Net Assets Ratio
NEWRON PHARMACEUT. EO-20 working capital to net assets ratio. NEWRON PHARMACEUT. EO-20 (NP5) has a Working Capital to Net Assets ratio of 108.2% as of December 2025. Working capital of €-12.04 Million (current assets of €38.05 Million minus current liabilities of €50.10 Million) is measured against net assets of €-11.13 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check NP5 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of NEWRON PHARMACEUT. EO-20 (2005–2025)
Working capital to net assets ratio of NEWRON PHARMACEUT. EO-20 from 2005 to 2025. This chart shows how NEWRON PHARMACEUT. EO-20's Working Capital to Net Assets ratio has evolved across 21 annual periods from 2005 to 2025. As of December 2025, the ratio stands at 108.2%, reflecting working capital of €-12.04 Million against net assets of €-11.13 Million EUR. See operational self-sufficiency of NEWRON PHARMACEUT. EO-20 to measure how many days the company can operate on defensive assets alone.
NEWRON PHARMACEUT. EO-20 Working Capital to Net Assets Ratio by Year (2005–2025)
NEWRON PHARMACEUT. EO-20 working capital to net assets ratio by year from 2005 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for NEWRON PHARMACEUT. EO-20 from 2005 to 2025, covering 21 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is NEWRON PHARMACEUT. EO-20's balance sheet.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 108.2% | €-12.04 Million | €-11.13 Million | €38.05 Million | €50.10 Million | ▼ -2470.5 pp |
| 2024 | 2578.7% | €37.60 Million | €1.46 Million | €61.10 Million | €23.51 Million | ▲ +2547.7 pp |
| 2023 | 31.0% | €-9.27 Million | €-29.91 Million | €19.65 Million | €28.93 Million | ▲ +198.2 pp |
| 2022 | -167.2% | €23.45 Million | €-14.03 Million | €28.49 Million | €5.04 Million | ▼ -1318.5 pp |
| 2021 | 1151.4% | €35.77 Million | €3.11 Million | €39.43 Million | €3.65 Million | ▲ +971.7 pp |
| 2020 | 179.6% | €30.98 Million | €17.25 Million | €37.87 Million | €6.89 Million | ▲ +71.2 pp |
| 2019 | 108.4% | €39.90 Million | €36.80 Million | €45.49 Million | €5.59 Million | ▲ +8.0 pp |
| 2018 | 100.4% | €55.08 Million | €54.84 Million | €59.51 Million | €4.43 Million | ▼ -0.1 pp |
| 2017 | 100.5% | €68.07 Million | €67.72 Million | €72.80 Million | €4.73 Million | ▲ +1.0 pp |
| 2016 | 99.5% | €49.49 Million | €49.75 Million | €56.14 Million | €6.64 Million | ▼ -1.4 pp |
| 2015 | 100.9% | €37.46 Million | €37.11 Million | €43.97 Million | €6.51 Million | ▲ +15.8 pp |
| 2014 | 85.1% | €24.90 Million | €29.26 Million | €29.39 Million | €4.49 Million | ▲ +10.5 pp |
| 2013 | 74.6% | €15.73 Million | €21.09 Million | €21.80 Million | €6.07 Million | ▼ -2.1 pp |
| 2012 | 76.7% | €21.16 Million | €27.61 Million | €32.75 Million | €11.59 Million | ▲ +3.7 pp |
| 2011 | 72.9% | €4.80 Million | €6.58 Million | €7.63 Million | €2.83 Million | ▲ +3.4 pp |
| 2010 | 69.5% | €8.47 Million | €12.19 Million | €13.11 Million | €4.63 Million | ▼ -9.3 pp |
| 2009 | 78.8% | €23.08 Million | €29.28 Million | €31.74 Million | €8.65 Million | ▼ -2.4 pp |
| 2008 | 81.3% | €37.23 Million | €45.81 Million | €47.24 Million | €10.01 Million | ▼ -22.8 pp |
| 2007 | 104.1% | €59.74 Million | €57.40 Million | €69.52 Million | €9.77 Million | ▼ -2.5 pp |
| 2006 | 106.6% | €72.34 Million | €67.86 Million | €85.13 Million | €12.79 Million | ▲ +11.7 pp |
| 2005 | 95.0% | €16.16 Million | €17.02 Million | €21.28 Million | €5.12 Million | — |